Eli Lilly to Reveal Study Data on Mesothelioma Drug Treatments Eli Lilly to Reveal Study Data on Mesothelioma Drug Treatments

li Lilly and Company will reveal the data from their latest research findings involving their mesothelioma and cancer treatment drugs, Alimta, Gemzar, and enzastaurin, an investigational drug. These studies are among more than 50 to be unveiled at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL. The results will reveal the effectiveness of these drugs in treating mesothelioma, especially in patients who cannot undergo surgery.

Alimta has been approved the FDA in combination for cisplatin (chemotherapy drug) for the initial treatment of non-small cell lung cancer (NSCLC).

Gemzar is used along with cisplatin for first-line treatment for patients with locally advanced or metastatic NSCLC for whom surgery isn't possible. It is also used to treat patients with pancreatic cancer, metastatic breast cancer, and ovarian cancer.

The studies will be presented at ASCO from May 29th to June 2nd 2009.